MA28036A1 - Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil - Google Patents
Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeilInfo
- Publication number
- MA28036A1 MA28036A1 MA28869A MA28869A MA28036A1 MA 28036 A1 MA28036 A1 MA 28036A1 MA 28869 A MA28869 A MA 28869A MA 28869 A MA28869 A MA 28869A MA 28036 A1 MA28036 A1 MA 28036A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- oxcarbazepine
- sleep
- pain
- improvement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne de nouvelles utilisations d'un dérivé de carbamazépine de formule (I) et de ses sels pharmaceutiquement acceptables. L'invention concerne en particulier un régime amélioré d'administration dudit dérivé de carbamazépine de formule (I) et desdits sels pharmaceutiquement acceptables dans le traitement de patients souffrant de douleurs, notamment de douleurs liées à la neuropathie, en particulier à la neuropathie diabétique, et dans l'amélioration du sommeil. L'invention concerne également l'utilisation d'oxcarbazépine dans la fabrication d'une composition pharmaceutique destinée à traiter la douleur ou d'une composition pharmaceutique destinée à améliorer le sommeil de patients souffrant de douleurs chroniques. L'invention concerne encore des compositions pharmaceutiques contenant de l'oxcarbazépine comme seul principe actif, destinées à traiter la douleur ou à améliorer le sommeil de patients souffrant de douleurs chroniques. L'invention concerne enfin des emballages contenant une composition pharmaceutique ayant pour seul principe actif de l'oxcarbazépine, ainsi que des instructions relatives au traitement de la douleur ou à l'amélioration du sommeil de patients souffrant de douleurs chroniques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0320637A GB0320637D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| US53737804P | 2004-01-16 | 2004-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28036A1 true MA28036A1 (fr) | 2006-07-03 |
Family
ID=34276821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28869A MA28036A1 (fr) | 2003-09-03 | 2006-03-10 | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060270658A1 (fr) |
| EP (1) | EP1663247B1 (fr) |
| JP (1) | JP2007513056A (fr) |
| KR (1) | KR20060118426A (fr) |
| AT (1) | ATE446759T1 (fr) |
| AU (1) | AU2004268381B2 (fr) |
| BR (1) | BRPI0414112A (fr) |
| CA (1) | CA2537060A1 (fr) |
| DE (1) | DE602004023861D1 (fr) |
| IL (1) | IL173822A0 (fr) |
| IS (1) | IS8373A (fr) |
| MA (1) | MA28036A1 (fr) |
| MX (1) | MXPA06002392A (fr) |
| NO (1) | NO20061515L (fr) |
| RU (1) | RU2369393C2 (fr) |
| SG (1) | SG146631A1 (fr) |
| TN (1) | TNSN06072A1 (fr) |
| WO (1) | WO2005020968A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| ATE496623T1 (de) * | 2006-04-26 | 2011-02-15 | Supernus Pharmaceuticals Inc | Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| KR102486435B1 (ko) | 2022-04-25 | 2023-01-10 | 주식회사 제이비플랜트 | 산업용 냉동기기의 친환경 패널의 제조 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| GB0128674D0 (en) * | 2001-11-30 | 2002-01-23 | Boots Co Plc | Treatment of sleep disorders and the like |
| BR0315374A (pt) * | 2002-10-17 | 2005-08-23 | Novartis Ag | Compostos orgânicos |
-
2004
- 2004-09-02 AU AU2004268381A patent/AU2004268381B2/en not_active Ceased
- 2004-09-02 MX MXPA06002392A patent/MXPA06002392A/es not_active Application Discontinuation
- 2004-09-02 CA CA002537060A patent/CA2537060A1/fr not_active Abandoned
- 2004-09-02 WO PCT/EP2004/009797 patent/WO2005020968A2/fr not_active Ceased
- 2004-09-02 SG SG200806736-5A patent/SG146631A1/en unknown
- 2004-09-02 AT AT04764755T patent/ATE446759T1/de not_active IP Right Cessation
- 2004-09-02 EP EP04764755A patent/EP1663247B1/fr not_active Expired - Lifetime
- 2004-09-02 BR BRPI0414112-1A patent/BRPI0414112A/pt not_active IP Right Cessation
- 2004-09-02 KR KR1020067004340A patent/KR20060118426A/ko not_active Ceased
- 2004-09-02 JP JP2006525105A patent/JP2007513056A/ja active Pending
- 2004-09-02 US US10/570,340 patent/US20060270658A1/en not_active Abandoned
- 2004-09-02 DE DE602004023861T patent/DE602004023861D1/de not_active Expired - Lifetime
- 2004-09-02 RU RU2006110550/15A patent/RU2369393C2/ru not_active IP Right Cessation
-
2006
- 2006-02-20 IL IL173822A patent/IL173822A0/en unknown
- 2006-03-02 TN TNP2006000072A patent/TNSN06072A1/en unknown
- 2006-03-10 MA MA28869A patent/MA28036A1/fr unknown
- 2006-03-24 IS IS8373A patent/IS8373A/is unknown
- 2006-04-03 NO NO20061515A patent/NO20061515L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20061515L (no) | 2006-06-06 |
| JP2007513056A (ja) | 2007-05-24 |
| EP1663247B1 (fr) | 2009-10-28 |
| AU2004268381A1 (en) | 2005-03-10 |
| CA2537060A1 (fr) | 2005-03-10 |
| BRPI0414112A (pt) | 2006-10-31 |
| RU2369393C2 (ru) | 2009-10-10 |
| TNSN06072A1 (en) | 2007-10-03 |
| WO2005020968A2 (fr) | 2005-03-10 |
| WO2005020968A3 (fr) | 2005-05-19 |
| SG146631A1 (en) | 2008-10-30 |
| ATE446759T1 (de) | 2009-11-15 |
| IL173822A0 (en) | 2006-07-05 |
| IS8373A (is) | 2006-03-24 |
| EP1663247A2 (fr) | 2006-06-07 |
| DE602004023861D1 (de) | 2009-12-10 |
| MXPA06002392A (es) | 2006-06-20 |
| KR20060118426A (ko) | 2006-11-23 |
| RU2006110550A (ru) | 2007-12-20 |
| US20060270658A1 (en) | 2006-11-30 |
| AU2004268381B2 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| US6221915B1 (en) | Pharmaceutical compositions | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| EA200300046A1 (ru) | Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию | |
| FR15C0009I2 (fr) | Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci | |
| WO2008027557A3 (fr) | Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité | |
| ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
| ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
| PL404315A1 (pl) | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku | |
| EA200600817A1 (ru) | Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты) | |
| WO2001047913A3 (fr) | Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale | |
| EA201100916A1 (ru) | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
| UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
| BRPI0415322A (pt) | composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina | |
| DK1675611T3 (da) | Terapeutiske anvendelser for C-peptid | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| TW200515912A (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| NO20053032L (no) | Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon. | |
| US20080293804A1 (en) | Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol) | |
| DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
| SE0000258D0 (sv) | Pharmaceutical preparation and method for treatment of diabetes | |
| JP2001089371A (ja) | ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤 | |
| DE60202299D1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| SE0000837D0 (sv) | New use |